Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA's Voyager 1 set to achieve historic distance from Earth - 2Ukrainian man arrested in Germany on suspicion of spying for Russia
- 3See a half-lit moon shine among the stars of Aquarius on Nov. 27
- 4Malaysian broadcaster rejects altered graphic about electricity rate hike
- 5Genome study reveals milestone in history of cat domestication
- Tehran synagogue damaged by missile strike according to Iranian media
- Electric discovery on Mars! Scientists find tiny lightning bolts coming from Red Planet dust clouds
- Foreign journalist kidnapped in Iraq: Interior Ministry
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- 3 moms, 3 countries, 1 very familiar problem: Why child care costs still don't add up for families
- Flu season is ramping up, and some experts are "pretty worried"
- How much would you pay to meet a Real Housewife? At BravoCon, the limit does not exist.
- As cases of a rare, deadly infection rise, doctors worry fewer teens will get vaccinated
- Allow Innovative Progressions To have a Massive Effect
